Nicolaus Copernicus Hospital

The medical center is at the forefront of hematology and oncology research, focusing on innovative treatments for myelofibrosis. The center is conducting advanced studies on the efficacy and safety of combining selinexor, a selective inhibitor of nuclear export, with ruxolitinib in treatment-naïve patients.

• Myelofibrosis Treatment
• Selinexor and Ruxolitinib Combination Therapy
• Anemia Response Evaluation

Through these studies, the center aims to enhance therapeutic strategies and improve patient outcomes in hematological malignancies.

Specializing in urology and regenerative medicine, the center is pioneering research on somatic cell-based therapies for urinary incontinence in patients post-radical prostatectomy. The focus is on evaluating the effectiveness and safety of injecting ATIMP within the urethral sphincter complex.

• Urinary Incontinence Management
• Somatic Cell-Based Therapy
• ATIMP Safety and Efficacy

This research is crucial in developing novel therapeutic approaches that aim to restore function and improve quality of life for patients with urinary complications.